Universe Pharma Posts $9M Revenue, $1.6M Loss; Unveils $10.75M All-Stock Deal
UPC sits 63% above its 52-week low of $2.
Summary
Universe Pharmaceuticals reported a narrower loss for the six months ended March 31, 2026, and disclosed a $10.75 million all-stock acquisition of Best Praise International.
Key Events · Earnings and Guidance · UPC
-
Revenue Flat, Loss Narrows
Revenue was $9.04 million, down 1.3% year-over-year. Net loss improved to $1.55 million from $3.28 million, primarily due to a $1.58 million decrease in consulting fees.
-
Cash Position Declines
Cash fell to $27.6 million from $33.6 million at September 30, 2025, driven by a $5.2 million deposit for the Best Praise acquisition and negative operating cash flow of $4.3 million.
-
$10.75M All-Stock Acquisition Announced
The company entered a Share Purchase Agreement to acquire Best Praise International for $10.75 million, payable entirely through the issuance of 4,376,552 Class A ordinary shares. The deal is expected to close in the second half of 2026.
-
CEO Receives 84,500 Shares Under New Equity Plan
The 2026 Equity Incentive Plan was adopted, and CEO Gang Lai was granted 71,890 Class A shares and 12,610 Class B shares as compensation for past services.
Analysis · UPC · Life Sciences
Universe Pharmaceuticals filed unaudited results for the six months ended March 31, 2026. Revenue held roughly flat at $9.04 million, but the net loss narrowed to $1.55 million from $3.28 million a year earlier, driven by a sharp drop in consulting fees. The company ended the period with $27.6 million in cash. More importantly, the filing reveals two subsequent events: the adoption of a 2026 Equity Incentive Plan and the grant of 84,500 shares to CEO Gang Lai, and a definitive agreement to acquire Best Praise International for $10.75 million, payable entirely in newly issued Class A shares. The all-stock acquisition, if completed, would significantly expand the company's footprint but also introduce substantial dilution for existing holders.
At the time of this filing, UPC was trading at $3.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $2.00 to $17.96. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.